Search clinical trials for: adalimumab (D2E7)

Total 536 results

Abbott

Completed

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Canada
Abbott

Completed

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis (ATLAS)

Ankylosing Spondylitis

United States
Abbott

Terminated

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira (VIVIR)

Rheumatoid Arthritis

Puerto Rico
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott

Completed

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Crohn's Disease

United States
AbbVie
Pivotal S.L.; Laboratorio Echevarne

Completed

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA)

Moderate to Severe Crohn's Disease
AbbVie

Completed

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Rheumatoid Arthritis

China
Abbott
Eisai Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Austria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Psoriasis

Psoriasis

Japan
Abbott

Completed

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) (ACCESS)

Crohn's Disease

United States
Abbott

Completed

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis (ReAct)

Rheumatoid Arthritis
Abbott

Approved for marketing

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab (PROWD)

Rheumatoid Arthritis
Abbott

Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie

Completed

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (VISUAL III)

Uveitis
AbbVie (prior sponsor, Abbott)

Completed

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

Ulcerative Colitis
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Belgium, Canada, Czech Republic, France, Netherlands, Poland, United Kingdom
Abbott

Completed

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Psoriasis

United States, Canada
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott

Approved for marketing

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis (ReAct)

Rheumatoid Arthritis
Abbott

Completed

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

Psoriasis

Canada
Abbott

Completed

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie (prior sponsor, Abbott)

Completed

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Enthesitis Related Arthritis (ERA)
Abbott

Completed

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Arthritis | Psoriatic
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott

Approved for marketing

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis (CanAct)

Rheumatoid Arthritis
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Arthritis | Psoriatic
AbbVie

Completed

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis
Abbott

Completed

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott

Completed

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Rheumatoid Arthritis

United States, Canada, Puerto Rico, Australia, Germany, United Kingdom
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

Ulcerative Colitis

United States, Austria, Belgium, Canada, Czech Republic, Germany, Hungary, Italy, Netherlands, Poland, Puerto Rico, Slovakia, Sweden
Abbott

Completed

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis
Abbott
Eisai Limited

Completed

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, New Zealand, Norway, Poland, Portugal, Spain, Switzerland
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
Abbott

Completed

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Denmark, Germany, Netherlands
Abbott

Completed

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
AbbVie (prior sponsor, Abbott)

Completed

Study of Adalimumab in Patients With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Netherlands, Spain, United Kingdom
Abbott

Completed

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Crohn's Disease

United States, Germany, Belgium, Canada, Netherlands, Italy, Austria, France
Abbott

Completed

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Arthritis, Juvenile Idiopathic

United States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
AbbVie (prior sponsor, Abbott)

Completed

The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States
AbbVie

Completed

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Rheumatoid Arthritis
AbbVie

Completed

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis (GPP) | Adalimumab | Japanese
Abbott

Completed

Long Term Open Label Continuation Study

Rheumatoid Arthritis

United States, Canada

3

Subscribe